|
Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment |
Lewis S W, Davies L, Jones P B, Barnes T R E, Murray R M, Kerwin R, Taylor D, Hayhurst K P, Markwick A, Lloyd H, Dunn G |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Lewis S W, Davies L, Jones P B, Barnes T R E, Murray R M, Kerwin R, Taylor D, Hayhurst K P, Markwick A, Lloyd H, Dunn G. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technology Assessment 2006; 10(17): 1-182 Authors' objectives The aim of this document is to determine the clinical and cost-effectiveness of different classes of antipsychotic drug treatment in people with schizophrenia responding inadequately to, or having unacceptable side-effects from, their current medication.
Authors' conclusions For band 1, there is no disadvantage in terms of quality of life and symptoms, or associated costs of care, over 1 year in commencing conventional antipsychotic drugs rather than new atypical drugs. Conventional drugs were associated with non-significantly better outcomes and lower costs. Drug costs represented a small proportion of the overall costs of care (<5%). For band 2, there is a statistically significant advantage in terms of symptoms but not quality of life over 1 year in commencing clozapine rather than new atypical drugs, but with increased associated costs of care. The results suggest that conventional antipsychotic drugs, which are substantially cheaper, still have a place in the treatment of patients unresponsive to, or intolerant of, current medication. Further analyses of this data set are planned and further research is recommended into areas such as current antipsychotic treatment guidance, valid measures of utility in serious mental illness, low-dose ,conventional- treatment in first episode schizophrenia, QLS validity and determinants of QLS score in schizophrenia, and into the possible financial and other mechanisms of rewarding clinician participation in trials.
INAHTA brief and checklist Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Aged; Antipsychotic Agents /adverse effects /economics /therapeutic use; Clozapine /adverse effects /therapeutic use; Females; International Classification of Diseases; Male; Middle Aged; Patient Satisfaction; Quality of Life; Schizophrenia /classification /drug therapy /economics; Treatment Outcome Language Published English Country of organisation England Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32006000736 Date bibliographic record published 16/06/2006 Date abstract record published 16/06/2006 |
|
|
|